Clinical Trial

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

Study acronym: PANORAMA

Recruiting Phase 2

Record status

This record was last updated April 25, 2023 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

Postoperative adjuvant chemotherapy followed by immunotherapy for non-small cell lung cancer has become a new treatment recommendation, but there are still many clinical problems to be solved in postoperative adjuvant immunotherapy. This study aims to explore the efficacy and safety of adjuvant chemotherapy combined with immunotherapy in patients with stage IIA-IIIA non-small cell lung cancer after surgery. Patients who meet the protocol and sign the informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed by maintenance with camrelizumab until one year or the disease progressed or unacceptable toxicity.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2023-04-21.

Trial Details

NCT Number	NCT05825443
Lead Sponsor	Nanfang Hospital, Southern Medical University Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions	Immunotherapy, Chemotherapy
Enrollment	57 participants
Start Date	2023-04-10
Primary Completion	2026-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2023-04-25